Randomized phase II trial of daily administration versus alternate-day administration of S-1 in patients with advanced non-small cell lung cancer
Aya Suzuki(Tokyo Medical and Dental University), Toshihiro Nukiwa(Tohoku University), Taku Nakagawa(Saint John's Health Center), Akira Inoue(Tohoku University Hospital), Takashi Yokoi(Kansai Medical University), Mariko Kanbe, Shunichi Sugawara(Sendai Kousei Hospital), Kazuhiro Usui(Hokkaido University Hospital), Kazuhiko Matsuno(Naha City Hospital), Kageaki Taima(Hirosaki University), Makoto Maemondo(Miyagi Prefectural Hospital Organization)
Cited by 6
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
|Cancer Cell|2012|1.4k
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2005|953